Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

BioLineRx Says First Patient Has Been Dosed In Phase 1 Trial Of Motixafortide As Monotherapy And In Combination With Natalizumab For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapies In Sickle Cell Disease

Author: Benzinga Newsdesk | December 21, 2023 08:02am

Posted In: BLRX